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Abstract: Human noroviruses in the family Caliciviridae are a major cause of epidemic 
gastroenteritis. They are responsible for at least 95% of viral outbreaks and over 50% of all 
outbreaks worldwide. Transmission of these highly infectious plus-stranded RNA viruses 
occurs primarily through contaminated food or water, but also through person-to-person 
contact and exposure to fomites. Norovirus infections are typically acute and self-limited. 
However,  disease  can  be  much  more  severe  and  prolonged  in  infants,  elderly,  and 
immunocompromised  individuals.  Norovirus  outbreaks  frequently  occur  in  semi-closed 
communities such as nursing homes, military settings, schools, hospitals, cruise ships, and 
disaster  relief  situations.  Noroviruses  are  classified  as  Category  B  biodefense  agents 
because  they  are  highly  contagious,  extremely  stable  in  the  environment,  resistant  to 
common disinfectants, and associated with debilitating illness. The number of reported 
norovirus  outbreaks  has  risen  sharply  since  2002  suggesting  the  emergence  of  more 
infectious strains. There has also been increased recognition that noroviruses are important 
causes of childhood hospitalization. Moreover, noroviruses have recently been associated 
with multiple clinical outcomes other than gastroenteritis. It is unclear whether these new 
observations  are  due  to  improved  norovirus  diagnostics  or  to  the  emergence  of  more 
virulent norovirus strains. Regardless, it is clear that human noroviruses cause considerable 
morbidity  worldwide,  have  significant  economic  impact,  and  are  clinically  important 
emerging  pathogens.  Despite  the  impact  of  human  norovirus-induced  disease  and  the 
potential for emergence of highly virulent strains, the pathogenic features of infection are 
not well understood due to the lack of a cell culture system and previous lack of animal 
models. This review summarizes the current understanding of norovirus pathogenesis from 
the histological to the molecular level, including contributions from new model systems. 
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1. Introduction 
Noroviruses constitute a genus within the family Caliciviridae. The human pathogens within this 
genus  cause  at  least  95%  of  nonbacterial  gastroenteritis  outbreaks,  and  50%  of  all  gastroenteritis 
outbreaks, throughout the world.  It is estimated that there are approximately 23 million norovirus 
infections per year in the United States alone, causing 50,000 hospitalizations and 300 deaths [1]. 
Based on a recent review of diagnostic studies testing for norovirus infections in clinical settings, it is 
estimated that they cause over one million hospitalizations and 200,000 deaths in young children in 
developing countries annually [2]. Noroviruses are highly transmissible and can spread via exposure to 
contaminated  food  or  water  sources,  person-to-person  contact,  aerosolized  vomitus  particles,  and 
fomites (Figure 1A). They are considered by CDC to be the most common cause of foodborne disease 
outbreaks [3]. Numerous features of norovirus infections have led to their classification as Category B 
biodefense  agents,  including  their  high  infectivity,  extreme  stability,  resistance  to  common 
disinfectants, and ability to cause incapacitating disease. Persons of all age groups are susceptible to 
infection  and  secondary  infections  are  common  [4–6].  In  recent  years,  there  has  been  a  dramatic 
increase in the number of reported norovirus outbreaks. These emerging RNA viruses have historically 
been very difficult to study but numerous advances in the field have begun to contribute to the overall 
understanding of norovirus pathogenesis.  
2. Clinical Disease and Epidemiology 
2.1. Clinical Disease 
In immunocompetent adults, the course of norovirus infection is rapid, with an incubation period of 
24–48 hours and resolution of symptoms within 12–72 hours [7]. Symptoms include vomiting and 
diarrhea with or without nausea and abdominal cramps. Low-grade fever and malaise can also develop. 
While norovirus infection typically causes an acute bout of gastroenteritis that resolves within days of 
the onset of symptoms, norovirus-induced disease can be much more severe and prolonged in specific 
risk  groups.  For  example,  infants  and  young  children  can  develop  more  severe  gastroenteritis 
following norovirus infection, with symptoms lasting up to six weeks [8–11]. Noroviruses have been 
reported  to  be  second  only  to  rotaviruses  in  causing  severe  childhood  gastroenteritis  [10,12]; 
considering  the  recent  success  in  vaccinating  infants  against  rotavirus  infections,  noroviruses  will 
likely become the most common cause of childhood diarrheal disease in the foreseeable future. In 
addition, prolonged symptomatic infection has been well-documented in transplant patients and other 
immunosuppressed individuals, with symptoms lasting over two years [13–19]. Similarly, norovirus 
infection can be particularly severe in the elderly, even resulting in death [20–23]. One recent study 
also reported that patients with inflammatory bowel disease may present with bloody diarrhea upon 
norovirus infection [24]. Viruses 2010, 2                         
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Figure 1. Norovirus outbreak characteristics. The Centers for Disease Control collected 
data from 232 norovirus outbreaks between July 1997 and June 2000. The results of this 
surveillance  are  summarized  here  for  the  source  of  virus  (A)  and  the  type  of  setting 
affected  by  the  outbreak  (B).  Data  are  reproduced  from  http://www.cdc.gov/ncidod/ 
dvrd/revb/gastro/norovirus-factsheet.htm. 
 
 
The  complete  scope  of  norovirus-induced  morbidity  worldwide  and  particularly  in  developing 
nations has been difficult to ascertain due to several factors (discussed in more detail elsewhere [20,25]). 
First, norovirus detection is difficult because these viruses cannot be propagated in cell culture and 
they are genetically variable, complicating RT-PCR-based detection assays. Second, there is a lack of 
reporting to health officials because of the acute nature of disease. Finally, national and international 
diagnostic/surveillance programs are not standardized, if present at all. Importantly though, there has 
recently been increased recognition of the burden of norovirus disease due to significant improvements 
in norovirus diagnostic assays and an increased awareness of the need for surveillance standardization. 
Along these lines, a global surveillance network called NoroNet (http://www.noronet.nl/noronet/) was 
recently  established  that  aims  to  monitor  norovirus  epidemics  in  an  effort  to  limit  their  scope. 
Continued efforts of this sort will be critical to delineate the global burden of norovirus disease.  
As  norovirus  diagnostics  have  improved,  there  have  been  numerous  reports  of  norovirus 
associations with clinical outcomes other than gastroenteritis. For example, one case report detected 
norovirus RNA in the serum and cerebrospinal fluid of a child with encephalopathy [26]. In addition, 
during a norovirus outbreak among military personnel in Afghanistan in May 2002, three infected 
patients  presented  with  gastroenteritis,  diminished  alertness,  headache,  neck  stiffness,  and  light 
sensitivity;  one  of  these  patients  also  displayed  disseminated  intravascular  coagulation  [27]. Viruses 2010, 2                         
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Noroviruses  have  also  been  implicated  in  necrotizing  enterocolitis  in  premature  infants  [28], 
postinfectious irritable bowel syndrome [29], and benign infantile seizures [30,31]. While these case 
reports provide only anecdotal evidence that norovirus infection can have varied clinical outcomes, 
they do suggest that noroviruses should be considered as potential etiological agents of diseases other 
than gastroenteritis.  
2.2. Genetic Diversity 
Noroviruses are classified in five genogroups (GI-GV), three of which (GI, GII, and GIV) contain 
primarily  human  viruses  [32,33].  Multiple  porcine  noroviruses  have  been  placed  in  GII  [34,35]. 
Genogroup III (GIII) contains bovine noroviruses [36,37] and GV contains murine noroviruses [38–42]. 
The genogroups are further subdivided into 31 distinct clusters or genotypes (8 GI, 19 GII, 2 GIII, 1 
GIV, and 1 GV genotypes) [4,32]. Norovirus strains are typically named after the location in which 
they  were  first  identified;  e.g.,  the  Farmington  Hills  strain  was  first  shown  to  be  responsible  for 
gastroenteritis cases in Farmington Hills, Michigan [43]. They are also commonly referred to by their 
genogroup and genotype; e.g., the Farmington Hills strain is a GII.4 (genogroup II, genotype 4) strain. 
Noroviruses display a wide degree of genetic variability – members within a genogroup differ by  
45–61% in their capsid genes, members within a genotype differ by 14–44%, and strains within a 
genotype differ by 0–14% [32]. This amount of intra-genus variation is high even compared to genera 
of other plus-strand RNA virus families [32]. This high degree of variability is undoubtedly one factor 
that complicates protective norovirus immunity. 
2.3. Epidemiology 
Norovirus outbreaks occur most commonly in semi-closed communities such as nursing homes, 
schools,  hospitals,  cruise  ships,  disaster  relief/evacuation  sites,  and  military  settings  (Figure  1B) 
[33,44–47]. Nosocomial norovirus outbreaks are one of the most common causes of hospital ward 
closures [48]. Outbreaks display wintertime seasonality, explaining why norovirus disease is referred 
to as the winter vomiting disease [49]. Several factors most likely contribute to the explosive nature of 
norovirus  outbreaks,  including  the  high  infectivity  of  norovirus  particles  [50],  the  persistence  of 
noroviruses  in  the  environment  [51–53],  prolonged  shedding  of  virus  from  both  symptomatic  and 
asymptomatic individuals [54–56], and a lack of lasting immunity [4–6].  In 2002,  a sharp rise in 
norovirus outbreaks worldwide was recognized which correlated with the emergence of a new virus 
variant, specifically a GII.4 norovirus strain [51,57]. Interestingly, researchers have determined that 
GII.4 strains resulted in pandemics in 1995–1996 (US95/96 strain) [33,58,59], 2002 (Farmington Hills 
strain) [43], 2004 (Hunter strain) [60], and 2006 (Minerva/2006b and Laurens/2006a strains) [61]. 
These  GII.4  variants  spread  rapidly  and  globally  and  are  thought  to  account  for  70–80%  of  all 
norovirus outbreaks at least since 2002 [62]. A recent study demonstrates that GII.4 strains associated 
with severe illness were circulating as early as 1974, and that the ancestral strain most likely emerged 
in the 1960s [63]. It is unclear why the GII.4 norovirus strains are so predominant but possibilities 
include increased environmental stability, transmissibility, and virulence [64].  
While it is widely accepted that noroviruses cause a majority of epidemic gastroenteritis worldwide, 
they have not received significant attention as a cause of sporadic gastroenteritis. However, improved Viruses 2010, 2                         
 
 
752
diagnostics has shed light on the unappreciated breadth of norovirus infection in this setting [12]. 
Based on numerous studies around the world, it is now recognized that noroviruses are an important 
cause  of  illness  in  hospitalized  children  (discussed  in  detail  in  several  recent  reviews  [12,25,65]), 
second to or as prevalent as rotavirus infections. They are also a previously unappreciated cause of 
traveler’s diarrhea [66–68]. 
3. Pathophysiology 
Because of the lack of a cell culture system and the historical lack of animal models of norovirus 
infection, the extent of our knowledge regarding pathogenesis of norovirus infection comes primarily 
from physical, histological, and biochemical studies of infected human volunteers. In recent years, 
work in porcine, bovine, and murine models has also begun to contribute to our understanding of 
norovirus pathogenesis. 
3.1. Histological Alterations in the Intestine 
Histological analysis of proximal intestinal biopsy samples from human volunteers that become ill 
after administration of either a GI (Norwalk; GI.1) or GII (Hawaii; GII.1) norovirus demonstrate an 
intact intestinal mucosa with specific histological changes, including broadening and blunting of the 
villi,  shortening  of  the  microvilli,  enlarged  and  pale  mitochondria,  increased  cytoplasmic 
vacuolization, and intercellular edema [69–72]. While abnormalities are apparent in intestinal epithelial 
cells  of  norovirus-infected  volunteers,  electron  microscopy  analysis  reveals  that  these  cells  remain  
intact [69,70]. Crypt cell hyperplasia has also been reported following norovirus infection [71,73]. Only 
proximal intestinal biopsies from infected individuals were obtained in early volunteer studies so it 
remains  to  be  determined  whether  the  distal  intestine  is  also  affected  by  norovirus  infection.  In 
addition to enterocyte changes, norovirus infection results in a mild inflammatory infiltration into the 
lamina  propria  that  has  been  observed  in  humans  infected  with  the  Norwalk  [69,71]  and  Hawaii 
viruses  [70,72],  gnotobiotic  calves  infected  with  the  human  GII.4  norovirus  HS66  [74],  and  mice 
infected with murine norovirus 1 (MNV-1) [75]. A recent study also reports an increased number of 
intraepithelial  cytotoxic  T  cells  in  the  duodenum  of  norovirus-infected  patients  0–6  days  after 
symptom onset [73]. While specific intestinal lesions are observed during the time of norovirus illness, 
they completely resolve within two weeks.  
Several  recent  studies  suggest  that  noroviruses  cause  apoptosis  of  enterocytes  in  humans  [73],  
pigs [76], and mice [75]. It is unclear whether viral infection of enterocytes directly induces apoptosis 
or whether a viral component secreted from other cells acts upon bystander enterocytes to induce their 
programmed cell death. Murine noroviruses and feline caliciviruses have been demonstrated to cause 
apoptosis of infected macrophages and epithelial cells, respectively, in vitro through the mitochondrial 
pathway [77–81], suggesting that apoptosis in vivo may be due to direct effects of infection. Troeger et 
al. postulate that the observed influx of intraepithelial CD8
+ lymphocytes during norovirus infection 
could cause enterocyte apoptosis upon perforin release [73]. Thus, it is possible that both direct and 
indirect mechanisms contribute to norovirus-induced apoptosis of enterocytes. Viruses 2010, 2                         
 
 
753
3.2. Physical and Biochemical Manifestations 
In one human volunteer study, it was observed that norovirus infection causes a marked delay in 
gastric emptying thought to be related to the high incidence of vomiting episodes during norovirus 
infections [82]. Such a pathophysiologic outcome to infection could be caused by an alteration of 
gastric motor functions or inflammation of the pyloric junction between the stomach and intestine. 
While mice lack an emetic reflex and thus do not vomit, it has been demonstrated that STAT1
−/− mice 
develop dramatic gastric bloating upon MNV-1 infection [75]. The recapitulation of delayed gastric 
emptying  in  a  small  animal  model  should  facilitate  a  mechanistic  dissection  of  the  basis  of  this 
outcome of norovirus infection. A transient malabsorption of D-xylose, fat, and lactose also occurs 
during acute norovirus infection [71,83]. This malabsorption correlates with shortened microvilli and 
decreased activity of specific brush border enzymes on enterocytes, including alkaline phosphatase, 
sucrase, trehalase, and possibly lactase [69]. It is presently unclear whether these changes are due to 
direct  virus-mediated  damage  to  enterocytes,  virus-induced  alterations  of  brush  border  enzyme 
expression  levels  (as  has  been  noted  for  rotavirus  [84]),  or  bystander/immunopathologic  effects. 
Moreover, it is unknown whether there is also a secretory component to norovirus-induced diarrhea.  
3.3. Systemic Infection 
While it has long been assumed that norovirus infection is confined to the intestine, there is no 
direct proof for this claim and several recent findings suggest that this dogma be re-considered. First, a 
recent study detected norovirus RNA in the serum of 15% of infected individuals [85]. Second, work 
in animal models of norovirus infection support virus dissemination past the intestine: (i) a transient 
viremia  was  detected  in  50%  of  gnotobiotic  pigs  infected  with  HS66  [76];  (ii)  one  of  five  
HS66-infected  gnotobiotic  calves  had  detectable  viral  RNA  in  their  serum  [74];  and  (iii)  murine 
noroviruses are well-documented to spread to mesenteric lymph nodes (MLNs) that drain from the 
intestine  [41,75,86–89] and  to  peripheral  tissues  [41,75,86,88,89].  In  particular,  MNV-1  replicates 
efficiently in the spleen and induces specific splenic histological changes, including activation of cells 
in the white pulp and hypertrophy of cells in the red pulp [75]. The physiological relevance of these 
splenic changes is unclear. The possibility that human noroviruses disseminate to peripheral sites is a 
clinically relevant question since mild or sporadic pathologies associated with human norovirus infection 
of peripheral tissues may have been missed due to the difficulties in their detection and the assumption 
that  they  are  limited  to  the  intestinal  tract.  Supporting  this  idea,  there  have  been  several  recent 
associations between norovirus infection and extraintestinal pathologies including encephalopathy [26], 
disseminated intravascular coagulation [27], and benign infantile convulsions [30,31]. Interestingly, 
rotaviruses have also recently been confirmed to spread to peripheral tissues and cause histological 
changes at these sites [90–92]. The mechanism of norovirus dissemination is unknown but at least the 
murine noroviruses infect dendritic cells (DCs), a cell type known to actively migrate from tissues to 
draining  lymph  nodes.  Thus,  it  is  possible  that  noroviruses  utilize  DC  infection  to  facilitate  their 
extraintestinal spread.  Viruses 2010, 2                         
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3.4. The Course of Norovirus Infection 
Norovirus  infections  are  typically  considered  to  be  short-lived,  lasting  for  only  a  few  days; 
however, increasing evidence points to prolonged (or perhaps persistent) infections in some scenarios. 
Although the symptoms caused by human norovirus infection typically resolve within several days, 
virus  particles  can  be  shed  from  asymptomatic  individuals  for  weeks  after  exposure  [54–56,93]. 
Further, symptomatic infection has been documented in immunosuppressed individuals with symptoms 
lasting for over 2 years [13–15] and in immunocompetent children with symptoms lasting for up to 6 
weeks [9,56]. Additionally, pigtail macaques infected with a human norovirus shed virus in their feces 
for  at  least  3  weeks  [94].  It  is  also  clear  that  murine  noroviruses  can  infect  wild-type  hosts  for  
weeks [41,86,87]. Interestingly, virus is detected not only in fecal samples of these mice but also in 
MLNs and in some cases intestines and spleens. Thus, there may be mucosal and extraintestinal sites 
of prolonged norovirus infection. Finally, it has long been recognized that feline caliciviruses establish 
chronic infections in cats, with animals continuing to shed virus for at least one month following 
infection and some even becoming life-long carriers [95]. Because these carrier cats are contagious, 
they  represent  an  important  reservoir  for  the  maintenance  of  feline  calicivirus  in  the  feline  
population  [96,97].  Overall,  noroviruses  can  infect  their  hosts  for  weeks  or  months  even  in  the 
presence of a fully functional immune system. Similar to the situation with feline caliciviruses, it is 
possible that individuals experiencing prolonged human norovirus infection act as reservoirs of virus, 
perpetuating its spread within a population. 
The reason(s) for prolonged norovirus infection is currently unclear but mechanisms underlying the 
ability of other viruses to establish persistence may logically play a role. A fundamental feature of 
persistent  viral  infections  is  that  the  host  immune  response  is  ineffective  at  completely  clearing 
infectious virus [98]. Consistent with this, adaptive immune cells are critical to limit the magnitude of 
norovirus infection since mice lacking B and T cells contain extremely high levels of MNV-1 within 
numerous tissues and feces for months following infection [39,99]. The inability to clear persistent 
infection with other viruses is commonly associated with viral evasion. For example, in persistent 
viruses such as hepatitis C virus (HCV) there is commonly an alteration of the antigenic epitopes 
encoded by the virus. Similarly, it has been demonstrated that the feline calicivirus genome acquires 
mutations  in  areas  predicted  to  be  important  for  immune  recognition  during  chronic  infection, 
suggesting that altered antigenicity plays a role in maintaining calicivirus persistence [100,101]. One 
study reports a similar accumulation of mutations within the hypervariable P2 capsid domain in a 
patient chronically infected with a human norovirus [15]. Interestingly, there is evidence for feline 
calicivirus that such progressive evolution of a single virus within a host accounts for only a minority 
of chronic infections; the majority appears to be instead due to cycles of sequential reinfection with 
either a variant of the same virus strain or with a different strain followed by a period of progressive 
evolution [102].  
Persistent viral infections are also commonly associated with impairment of the normal functioning 
of immune cells upon infection. Although there is currently no direct evidence that noroviruses impair 
immune  function,  it  is  interesting  to  note  that  murine  noroviruses  infect  DCs  [103]  since  many 
persistent viruses target this cell type and specifically impair their ability to activate T and B cells [98]. Viruses 2010, 2                         
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Overall,  the  mechanisms  by  which  noroviruses  maintain  prolonged  infection  remain  incompletely 
understood, but they may play a critical role in impairing adaptive immune responses such that they 
fail  to  protect  from  secondary  challenge.  It  will  be  interesting  in  future  studies  to  examine  the 
relationship between prolonged norovirus infection and the lack of protective immunity elicited by 
primary  infection.  Prolonged  virus  shedding  from  individuals  in  whom  symptomatic  infection  has 
resolved also surely contributes to the difficulty in controlling norovirus outbreaks. 
4. Cellular Determinants of Norovirus Pathogenesis 
The precise cell tropism of human noroviruses is unknown. When intestinal biopsy sections from 
volunteers infected with either a GI.1 or a GII.1 norovirus were analyzed by electron microscopy, virus 
particles were not observed [70,83], leading investigators to postulate that human noroviruses infect 
very few cells in vivo. This hypothesis is supported by work in animal models (described below). 
Furthermore, numerous attempts to identify a relevant cell culture system for these viruses have been 
unsuccessful [104]. The inability to propagate human noroviruses has long been the major obstacle to 
studying  this  virus  family.  However,  numerous  recent  advances  in  this  field  offer  promise  of 
overcoming this barrier. Moreover, recent work in animal models suggests that multiple intestinal cell 
types  including  enterocytes,  macrophages  (Mφs),  and  DCs  may  support  at  least  low  level  in  vivo 
replication.  
4.1. Recent Advances of In Vitro Human Norovirus Infection Models  
Extensive efforts have failed to detect norovirus replication in intestinal epithelial cell lines [104]. 
There has been a single report describing human norovirus infection of a 3-dimensional model of 
human small intestinal epithelium [105]; however, several independent laboratories failed to detect 
increased viral genome in these cells during the period of noted cytotoxicity, strongly suggesting that 
cellular pathology was not due to viral replication [106]. Based on the tropism of murine noroviruses 
for DCs and Mφs [103], in vitro infections of human DCs and Mφs derived from monocytes isolated 
from peripheral blood mononuclear cells (PBMCs), or myeloid DCs directly isolated from PBMCs, 
were performed with the G1.1 Norwalk virus. There was no evidence for viral replication in these cells 
(Lay  MK,  Atmar  RL,  Guix  S,  Bharadwaj  U,  He  H,  Neill  FH,  Sastry  JK,  Yao  Q  and  Estes  MK, 
manuscript in preparation). While these results demonstrate that at least one human norovirus does not 
infect  peripheral  DCs  and  Mφs  in  vitro,  DCs  and  Mφs  can  differ  significantly  in  pathogen 
susceptibility depending on their source and differentiation [107–109]; thus it remains possible that 
other types of DCs and Mφs (i.e., mucosal cells) are permissive to human noroviruses. 
Based on several recent studies, it is now clear that the block to human norovirus propagation in 
vitro occurs at the level of receptor binding, internalization, or genome uncoating. Specifically, Guix et 
al. demonstrated that transfecting norovirus RNA into Huh-7 cells results in a complete single round of 
viral  replication  culminating  in  progeny  virion  release  [110].  Furthermore,  transfection  of 
nonpermissive cells with infectious norovirus clones driven by either the T7 polymerase or the host 
RNA  polymerase  II  results  in  genome  replication  and  virion  production  [111–114].  Similarly,  a 
norovirus replicon has  been  generated that  results in genome replication and nonstructural protein Viruses 2010, 2                         
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production in stably transfected cells [115]. Overall, it can be concluded that bypassing the initial steps 
of virus entry and uncoating overcomes the block to norovirus replication in cultured cells.  
4.2. Human Norovirus Cell Tropism in Animal Models  
Both gnotobiotic pigs and gnotobiotic calves are susceptible to infection with at least one human 
norovirus,  a  GII.4  virus  called  HS66  [74,76].  Infected  pigs  and  calves  develop  diarrhea  and 
histopathological changes are evident in the intestines of infected calves. In HS66-infected gnotobiotic 
pigs,  virus  particles  are  apparent  in  cytoplasmic  vesicles  within  enterocytes  [76].  Moreover,  viral 
capsid can be detected in enterocytes located at villous tips and along the sides of villi, but rarely in 
crypts, of the duodenum and jejunum (Figure 2A). Nonstructural protein indicative of viral replication 
can also be detected in a limited number of enterocytes. In HS66-infected gnotobiotic calves, viral 
structural protein is detectable in enterocytes (Figure 2B) and in lamina propria cells resembling Mφs 
along the jejunum and ileum, but not along the duodenum [74]. The discrepancy between these animal 
model studies and earlier studies that failed to detect virus in human intestinal sections could be due to 
(i) virus strain-dependent differences (GII.4 versus GI.1 and GII.1 viruses, respectively); (ii) virus dose 
differences;  (iii)  species-specific  disparities  in  norovirus  infection;  or  (iv)  differences  in  assay 
sensitivity between studies.  
Figure 2. The intestinal cell tropism of HS66 in gnotobiotic pigs and calves. (A) Paraffin-
embedded sections of the duodenum of HS66-infected  gnotobiotic pigs prepared 4 dpi 
were stained with a monoclonal antibody against the GII human norovirus capsid protein 
(called  NS14).  Fluorescently  conjugated  anti-mouse  secondary  antibody  facilitated 
visualization of capsid through immunofluorescent confocal microscopy (in green). Nuclei 
were stained with propidium iodide (in red). Data are reproduced from J. Virol. 2006, 80, 
10372–10381.  (B)  Paraffin-embedded  sections  of  the  jejunum  of  HS66-infected 
gnotobiotic calves prepared 3 dpi were stained with NS14. Viral capsid was visualized 
through immunohistochemistry. Data are reproduced from J. Virol. 2008, 82, 1777–1786. 
A. Capsid detection in pigs
B. Capsid detection in calves
 Viruses 2010, 2                         
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4.3. Murine Norovirus Cell Tropism 
A number of murine norovirus strains have now been isolated from mouse colonies in academic 
research settings around the world [39–42,86]. Murine noroviruses are enteric in nature: (i) most strains 
were originally isolated from fecal samples or MLNs; (ii) they are infectious orally and can be detected 
in mucosal sites (intestines, MLNs) during infection; and (iii) they are shed in feces [39–42,75,86]. At 
least one murine norovirus causes decreased fecal consistency and mild intestinal inflammation in 
infected wild-type mice, and severe gastroenteritis in STAT1
−/− mice [75,88]. Murine noroviruses are 
known to replicate in DCs and Mφs, but not other cell types, in vitro [39–41,86,103,116,117]. Moreover, 
in MNV-1-infected wild-type mice, viral nonstructural protein can be detected in lamina propria cells 
morphologically resembling DCs and Mφs of rare intestinal villi at 24–48 hpi (Figure 3A) [75]. The in 
vivo infection of DCs and Mφs by MNV-1 is further supported by the immunohistochemical detection 
of MNV-1 antigen in cells that resemble Mφs in the liver, and Mφs and DCs in the spleen [103]. It has 
also been reported that immunodeficient mice naturally infected with a murine norovirus contain viral 
antigen in the cytoplasm of inflammatory  cells in the liver, splenic  red and white pulp, intestinal 
lamina propria, intestinal lymphoid follicles, lung, pleural and peritoneal cavities, and MLNs [89,118]. 
In the absence of an intact interferon signaling pathway, MNV-1 antigen is detected more abundantly 
and in additional intestinal cell types of infected mice. Specifically, viral antigen can be detected in 
enterocytes of STAT1
−/− mice at 12 hpi (Figure 3B), and lamina propria and Peyer’s patch cells at 24–
48 hpi (Figure 3C) [75]. Thus, interferon may restrict the cell tropism of noroviruses, as has been 
shown for a number of other viruses [119–121]. If this is the case, norovirus strains with differing 
sensitivity to interferon responses may display disparate cell tropism.  
Figure 3. The intestinal cell tropism of MNV-1 in wild-type and STAT1
−/− mice. Intestinal 
sections prepared from MNV-1-infected 129SvEv (A) or STAT1
−/− (B and C) mice were 
stained  with  guinea  pig  polyclonal  antibody  raised  against  the  MNV-1  Pro:Pol 
nonstructural  protein.  Fluorescently  conjugated  secondary  antibody  was  then  used  to 
visualize viral protein through immunofluoresence, in which viral protein is pseudocolored 
in green and nuclei in blue. Data are reproduced from J. Virol. 2007, 81, 3251–3262. 
A. 129SvEv, 24 hpi B. STAT1-/-, 12 hpi
C. STAT1-/-, 48 hpi
60X
40X 20X
60X
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4.4. Norovirus Receptors 
Human  noroviruses  recognize  histo-blood  group  antigens  (HBGAs)  that  are  expressed  on  the 
surface of mucosal epithelial cells [122]. HBGAs are neutral carbohydrates linked to proteins or lipids 
on  cell  surfaces.  The  glycosyltransferases  that  control  their  synthesis  are  encoded  by  the  highly 
polymorphic ABO, Lewis, and secretor gene families. The association of noroviruses with HBGAs has 
been  demonstrated  to  be  essential  for  certain  virus  strains.  This  is  best  exemplified  by  the  strict 
correlation  between  secretor  status  and  susceptibility  to  Norwalk  virus  infection  –  Norwalk  virus 
recognizes a1,2-linked fucose residues [63] whose expression on gut epithelial cells and in body fluids 
is dependent on a wild-type FUT2 gene; while individuals with a wild-type FUT2 gene (~80% of the 
population; referred to as secretors) are susceptible to Norwalk virus infection, individuals that contain 
a null FUT2 allele (~20% of the population; referred to as nonsecretors) are completely resistant [123].  
A number of distinct norovirus strain-specific binding profiles have been reported [124–126]. As 
described recently by Tan et al., strains can be segregated generally into those that bind A/B epitopes 
and those that bind Lewis epitopes [127]. While GI and GII strains are contained within both binding 
categories, there are genogroup-specific differences in the receptor binding interface of the norovirus 
capsid that interacts with the HBGA. Thus, even if a GI and a GII norovirus interact with the same 
HBGA, the precise residues involved in this binding will most likely be different (Figure 4). In terms 
of the highly prevalent GII.4 noroviruses, strains circulating in 1974, 1977, and 1987 all display a 
common HBGA binding pattern (H type 3, Lewis
Y, and B antigens); a strain circulating in 1997 binds 
the same set of HBGAs in addition to A and Lewis
B antigens; a strain isolated from a 2002 outbreak 
displays a unique HBGA pattern (Lewis
A, Lewis
X, and A antigens); and another 2002 strain in addition 
to strains isolated from 2004 and 2005 outbreaks fail to bind efficiently to any HBGA suggesting they 
may bind other carbohydrates [63,128]. Interestingly, a strain circulating in 2006 displays a similar 
HBGA binding profile to the 1997 pandemic strain [129]. While norovirus strains display distinct 
HBGA binding properties, collectively they can infect nearly all individuals due to their high genetic 
variability [130]. This highlights the highly adaptive nature of noroviruses and the likelihood of a long 
co-evolution of human noroviruses with their human host.  
Several animal caliciviruses also bind HBGAs, including the highly virulent rabbit hemorrhagic 
disease virus that segregates within the lagovirus genus [131] and the Tulane virus isolated from rhesus 
macaques  that  defines  the  newly  proposed  recovirus  genus  [127,132].  Conversely,  other  animal 
caliciviruses, including multiple feline calicivirus strains [133] and murine norovirus strains [134], 
bind sialic acid on permissive cells. Thus, carbohydrate binding appears to be conserved across the 
Caliciviridae family while specific members can bind neutral or negatively charged residues (Figure 5). 
There are examples of human noroviruses that do not bind HBGAs, including recent GII.4 pandemic 
strains [125,128]; it has yet to be determined whether these strains instead bind negatively charged 
sugars similar to feline caliciviruses and murine noroviruses. Evidence supporting this possibility is 
provided  by  studies  demonstrating  binding  of  GII  noroviruses  to  negatively  charged  heparan  
sulfate [135] and sialylated Lewis
x carbohydrate [136].  
Even though HBGA association is essential for in vivo Norwalk infection, it is not sufficient to 
overcome  the  block  to  in  vitro  virus  propagation  –  cell  lines  expressing  HBGAs  are  resistant  to 
infection [104] and transfection of FUT2 into cells does not facilitate infection [110]. These observations Viruses 2010, 2                         
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suggest that binding to an as-yet-unidentified entry receptor is also a required event. This is supported 
by the identification of both JAM-A and sialic acid as receptors for feline calicivirus [133,137]. It is 
even possible that cells expressing HBGAs are not the true target of norovirus infection. For example, 
binding to HBGA expressed on the surface of enterocytes may mediate norovirus attachment to the 
intestinal wall while binding to an alternative receptor on a neighboring cell type (i.e., DCs and Mjs) 
is required to trigger entry and subsequent replication. 
5. Molecular Determinants of Norovirus Pathogenesis  
Understanding the molecular aspects of viral replication can facilitate the development of rational 
therapies. In this section, we summarize recent findings of norovirus replication mechanisms that may 
contribute to norovirus pathogenesis and ultimately lead to the design of novel antiviral strategies.  
Figure  4.  The  HBGA  binding  interface  on  norovirus  particles  is  genogroup-specific. 
Crystal structures have been determined for P dimers of a representative GI norovirus (A) 
and a representative GII norovirus (B) complexed with HBGA. Surface models are shown 
here, with P dimers colored gray (one monomer is darker gray than the other) and the three 
major components of the HBGA binding interface colored green, red, and orange. The 
HBGA is colored yellow. While the binding sites on both viruses lie within the exposed P2 
domain, the exact residues and HBGA binding mode differ. Moreover, note that the HBGA 
binding interface of Norwalk virus is located within a single monomer while the interface 
of VA387 spans both monomers. Data are reproduced from PLoS ONE 2009, 4, e5058. 
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Figure 5. The known carbohydrate binding partners of caliciviruses. At least one member 
from four of the six calicivirus genera (colored in purple) has been demonstrated to bind a 
carbohydrate, suggesting that the original calicivirus ancestor was a carbohydrate binder. 
Similarly, three of the five norovirus genogroups (colored in blue) have been shown to 
contain members that bind carbohydrates. Two of the three norovirus genogroups containing 
human members have been shown to specifically bind HBGAs, either A/B/H antigens (A/B) 
or  Lewis  antigens  (Lewis).  Representative  virus  strains  and  their  known  carbohydrate 
ligands are shown in orange. Data are adapted from PLoS ONE 2009, 4, e5058. 
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5.1. Norovirus Genomic Structures 
Noroviruses have plus-stranded linear RNA genomes of 7.4–7.7 kb which are typically organized 
into three open reading frames (ORF1-3) (Figure 6) [138–140]. Murine noroviruses have a predicted 
fourth ORF overlapping ORF2 but in an alternate reading frame [41]; it has yet to be determined 
whether this ORF codes for a functional protein. The 5’ proximal region of the norovirus genome 
encodes  all  of  the  nonstructural  proteins  in  a  single  ORF  (ORF1)  while  the  3’  proximal  region, 
transcribed  into  a  subgenomic  message,  encodes  the  major  and  minor  structural  proteins  in  two Viruses 2010, 2                         
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separate  ORFs  (ORF2  and  ORF3,  respectively).  Norovirus  genomes  are  thought  to  be  covalently 
associated with a viral protein called VPg at their 5’ ends and are polyadenlyated at their 3’ ends.  
Figure 6. Norovirus genomic organization and protein function. (A) Norovirus genomes 
are comprised of a single linear piece of positive-sense RNA between 7.4–7.7 kb. They 
contain three open reading frames, one encoding a polyprotein of 7 nonstructural protein 
products (colored in green), one encoding the major structural capsid protein VP1 (colored 
in orange), and one encoding the minor structural protein VP2 (colored in purple). There is 
a short overlap between ORFs 1 and 2. A subgenomic mRNA that is 3’ co-terminal with 
full-length  genomes  is  produced  during  norovirus  replication.  This  mRNA  acts  as  a 
template for the production of structural proteins; similar to genomic RNA, it is covalently 
linked to VPg at its 5’ end and polyadenylated at its 3’ end. (B) Known and hypothesized 
functions of mature norovirus proteins. 
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Essential viral genomic structures represent putative antisense drug targets. Moreover, identification 
of essential RNA elements within the viral genome may facilitate the construction of viruses with a Viruses 2010, 2                         
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dominant inhibitory effect on the replication of wild-type virus [141]. Recent bioinformatic analyses of 
calicivirus genomes have identified conserved secondary structures that include: (i) two or more 5’ 
terminal stem-loops; (ii) a 3’ terminal hairpin; (iii) a stem-loop just upstream of the ORF1/2 junction in 
the antigenomic strand proposed to be a component of the subgenomic promoter; and (iv) a stem-loop 
at the 5’ end of the polymerase coding region with a motif characteristic of picornavirus cre elements 
that dictate VPg uridylylation [142,143]. Several of these structures were determined to be critical for 
the replication of a murine norovirus [142].  
5.2. Norovirus Nonstructural Proteins  
Norovirus  ORF1  encodes  a  large  polyprotein  that  is  cleaved  into  seven  mature  nonstructural 
proteins  (NS1-NS7)  [144–146].  A  number  of  these  proteins  have  defined  activities,  including  an 
NTPase (NS3) [147], a protease (Pro; NS6) [148], and an RNA-dependent RNA polymerase (Pol; 
NS7) [149,150]. Noroviruses also encode a VPg (NS5) that, based on work with animal caliciviruses, 
is presumed to be covalently attached to the 5’ ends of viral genomes in place of a typical 5’ cap 
structure [151–153]. The norovirus VPg can function as a primer in viral RNA replication following its 
uridylylation [150,154]. However, the norovirus Pol can also initiate RNA polymerization in a primer-
independent  manner;  it  has  been  postulated  that  it  uses  uridylylated  VPg  primer-mediated 
polymerization to replicate polyadenylated genomes and primer-independent polymerization to copy 
antigenomes  [149,150].  The  norovirus  VPg  also  interacts  with  host  translation  initiation  factors, 
perhaps to recruit them to the 5’ end of the RNA genome for translation initiation [155–157].  
A number of the norovirus nonstructural proteins do not share significant sequence homology to 
proteins of known function, including NS1, NS2, and NS4 [4], and their functions in viral replication 
are only beginning to be unraveled. While there is no information available on the role played by the 
most amino-terminal protein NS1 in norovirus replication, NS2 (also referred to as p48 and the N 
terminal protein) has been shown to co-localize with the Golgi complex in transfected cells and induce 
rearrangement of the Golgi membrane [158]. It also interacts with a host protein involved in regulating 
vesicle transport and can inhibit cell surface expression of proteins [159]. Expression of NS4 (also 
referred to as p22 and the 3A-like protein) in transfected cells has recently been shown to induce Golgi 
disruption. Moreover, NS4 contains a novel ER export signal that results in aberrant trafficking of 
COPII-coated  vesicles  and  ultimately  in  inhibition  of  host  protein  secretion  (Sharp  TM,  Guix  S, 
Katayama  K, Crawford  SE and Estes MK, manuscript submitted). Redistribution of COPII-coated 
vesicles was not observed during MNV-1 infection of RAW264.7 cells [160], suggesting that human 
and murine noroviruses may differentially affect secretory pathways. Overall, available data suggest 
that  norovirus  NS2  and  NS4  proteins  both  contribute  to  viral  replication  complex  formation  on 
intracellular membranes including that of the Golgi apparatus. This is supported by work with MNV-1, 
demonstrating that all nonstructural proteins localize to the ER, Golgi bodies, and early endosomes, 
but  not  to  late  endosomes  or  lysosomes  [160].  One  can  postulate  that  NS2  and  NS4  disrupt 
intracellular  host  protein  trafficking,  which  may  play  an  important  role  in  the  pathogenesis  of 
norovirus  infections  by  blocking  surface  expression  (i.e.,  MHC  molecules)  and  secretion  (i.e., 
cytokines) of immune mediators in infected cells.  Viruses 2010, 2                         
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Any of the essential activities encoded by norovirus nonstructural proteins could potentially be 
targeted with antiviral compounds for intervention. In addition, immunotherapeutic strategies based on 
enhancing the host cell’s normal antiviral mechanisms may be engineered to disrupt the function of 
one or more norovirus nonstructural proteins. For example, during MNV-1 infection of permissive 
cells,  translation  of  nonstructural  proteins  can  be  inhibited  by  both  type  I  and  type  II  interferon 
responses  [161].  A  host  innate  immune  mediator  induced  by  interferon  may  thus  block  required 
interactions  between  norovirus  VPg  and  translation  initiation  factors,  representing  a  candidate 
immunotherapeutic to treat norovirus infections. Both type I and type II interferon also inhibit the 
replication of a human norovirus expressed from a replicon in transfected cells [115,162]; it has yet to 
be determined whether these responses target norovirus translation as they do in the murine system. 
5.3. Norovirus Structural Proteins  
Noroviruses are nonenveloped icosahedral viruses between 27–30 nm in diameter. Norovirus ORF2 
encodes the major structural protein called VP1 or capsid. Virions contain 180 copies, or 90 dimers, of 
VP1 that assemble into icosahedral particles exhibiting T = 3 symmetry [163–167]. Each capsid dimer 
forms an arch-like protrusion extending from the internal shell of the particle. The capsid protein itself 
can be divided into a conserved internal shell domain (S) and a more variable protruding domain (P) 
that forms the arch-like protrusions. The P domain can be further subdivided into P1 and P2 domains, 
with P1 forming the sides of the arches and P2 located at the exposed tops of the arches. Expression of 
VP1  independent  of  other  viral  components  results  in  the  self-assembly  of  virus-like  particles  
(VLPs) [168], and expression of solely the P domain of VP1 results in the formation of P dimers as 
well as P particles composed of 12 P dimers [169]. These structures retain the binding properties of 
native norovirus virions, at least in terms of carbohydrate association, and have been extremely useful 
in binding and antigenicity studies in the absence of a cell culture system [170]. Consistent with its 
exposed location on the virion surface, the P2 domain of VP1 comprises a hypervariable region that is 
suspected to contain receptor binding and antigenic sites. Indeed, numerous structural and mutagenesis 
studies  of  VLPs  and  P  domain  structures  have  confirmed  that  the  binding  interface  for  HBGA 
association with norovirus particles resides in the P2 domain of capsid [169,171–175]. Furthermore, 
monoclonal antibodies have been demonstrated to recognize conformational epitopes located in the P2 
domain [176,177]. Identifying critical determinants of norovirus receptor binding and antigenicity may 
be instrumental in the design of effective therapeutics and vaccines. Interestingly, a single amino acid 
change  in  the  P2  domain  of  a  murine  norovirus  has  been  associated  with  its  in  vivo  
attenuation [103,178].  
Norovirus ORF3 encodes a minor structural protein called VP2 that is present in only 1–2 copies 
per virion [138,179]. VP2 is small, basic, and quite divergent in both size and sequence between 
viruses within this family. Its function in viral replication is currently undefined but there is evidence 
that it increases the expression level of VP1 and that it stabilizes VLPs [180]. The basic charge of VP2 
suggests that it may function in encapsidation of the viral genome.  
Both VP1 and VP2 are translated from a subgenomic message that is polyadenylated and, based on 
work with feline caliciviruses [152], is presumed to be covalently attached to VPg at its 5’ end. While 
expression of VP1 is presumed to occur via VPg-directed translation initiation (similar to expression of Viruses 2010, 2                         
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nonstructural proteins from genomic RNA), the mechanism for translation initiation of the downstream 
VP2 protein was unclear until recently. There is now evidence from several animal caliciviruses that 
translation  of  VP2  proceeds  via  a  translation  termination  re-initiation  (TTR)  mechanism.  In  this 
process, posttermination ribosomes from VP1 translational events remain associated with subgenomic 
RNA  through  interactions  with  termination  upstream  ribosomal  binding  sites  (TURBSs)  in  the  3’ 
proximal  end  of  VP1,  facilitating  recruitment  of  translation  initiation  factors  to  the  5’  end  of  
VP2 [181–184]. At least one of the TURBS is conserved across the Caliciviridae family, suggesting 
that noroviruses rely on the same mechanism for VP2 expression [181]. A recent study also suggests 
that  TTR  is  used  by  at  least  one  norovirus  to  express  VP1  independent  of  subgenomic  message 
production [185]; while this most likely contributes minimal amounts of capsid compared to the levels 
produced from translation of subgenomic RNA, the authors speculate that VP1 may play an additional 
nonstructural role(s) in the viral replication cycle. 
6. Norovirus Immunity and Vaccination 
6.1. Immunity  
Immunity to noroviruses is complicated by the heterogeneous responses of the human population 
and the transient nature of immunity in some individuals. These atypical responses are best highlighted 
by  early  studies  in  which  volunteers  were  repeatedly  exposed  to  homologous  virus  inoculum 
comprised of filtered stool from norovirus outbreak patients [5,6]. In these studies, several patterns of 
susceptibility  were  noted  –  a  proportion  of  volunteers  were  resistant  to  primary  and  subsequent 
infections,  and  a  proportion  of  individuals  were  equally  susceptible  to  primary  and  secondary 
infections when there was at least a six-month interval between challenges. One possible explanation 
for the continued susceptibility of a subset of individuals is that they fail to generate a virus-specific 
immune  response  upon  norovirus  infection.  However,  data  gathered  from  many  human  volunteer 
challenge studies and natural norovirus outbreaks conclusively show that people do develop a virus-
specific antibody response and that the presence of this response does not correlate with protection 
[5,6,93,123,186–189].  Specifically,  virus-specific  serum  IgG  is  induced  and  persists  for  months 
following infection, while serum IgA and IgM responses are more short-lived. Mucosal IgA is induced 
as well but its duration has not been determined [190]. Because there is no cell culture system for 
human noroviruses, it has not been possible to determine whether norovirus-specific antibodies are 
neutralizing. However, a surrogate assay based on inhibition of VLP binding to HBGA ligands has 
been  used  to  demonstrate  that  virus-specific  serum  antibodies  generated  during  experimental  and 
natural  infections  neutralize  carbohydrate  binding  [128,129,191,192].  Moreover,  traditional 
neutralization assays are possible for murine noroviruses because they are cultivable. MNV-1 infection 
of  mice  induces  neutralizing  serum  antibodies  [103]  and  one  MNV-1-neutralizing  monoclonal 
antibody has been shown to bind each of the 180 hypervariable P2 domains of native MNV-1 virions 
without inducing a major conformational change, suggesting that neutralization in this case is mediated 
by abrogation of cellular attachment [167]. Nevertheless, the duration of norovirus antibody responses 
has not been clearly defined, so it remains possible that waning humoral immunity is related to the 
susceptibility of some previously exposed individuals to repeat norovirus infections. Viruses 2010, 2                         
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While there have been no direct studies of T cell responses to human norovirus infection, surrogate 
cytokine studies suggest that virus-specific T cells are also induced in infected individuals. In one 
study, peripheral blood mononuclear cells (PBMCs) were collected from norovirus-infected volunteers 
at  pre-challenge  and  post-challenge  time  points,  incubated  with  norovirus  VLPs,  and  secretion  of 
cytokines from the PBMCs was measured [193]. The authors noted increases in the Th1 cytokines 
IFNg and IL-2, as well as the Th2 cytokine IL-5. Notably though, similar increases in cytokine levels 
were  observed  when  pre-challenge  and  post-challenge  PBMCs  from  uninfected  individuals  were 
compared to each other, presumably indicating that controls in this study were previously exposed to 
natural  norovirus  infection.  This  finding  highlights  the  difficulty  of  studying  primary  immune 
responses to human noroviruses where infection histories are impossible to discern. Recent studies in 
the gnotobiotic pig and calf models also report moderate increases in several Th1 and Th2 cytokines as 
well as interferon in the serum and intestinal contents of infected animals, suggestive of a T cell 
response upon primary challenge [74,194]. Overall, the available information on secondary human 
norovirus  infections  supports  an  atypical  pattern  of  immunity  in  which  some  previously  exposed 
individuals are susceptible to repeat infections even in the face of virus-specific memory immune 
responses. Another subset of individuals is resistant to infection, presumably due to genetic resistance 
(i.e., nonsecretors) or preexisting immunity. 
In the early volunteer challenge studies, it was noted that susceptible individuals were protected 
from disease when re-challenged soon after secondary exposure (<6 months) in contrast to a more 
distant  re-challenge  (>6  months)  [5,6],  suggesting  that  short-term  norovirus  immunity  is  elicited 
whereas  long-term  immunity  is  not.  Studies  of  murine  norovirus  infection  lend  support  to  this 
explanation – a primary MNV-1 exposure results in reduced virus loads upon re-challenge when the 
interval between primary and secondary infections is short (Figure 7; 6-week challenge), although it is 
important to note that this magnitude of protection is insufficient to protect the host from disease [88]. 
While  protective  peripheral  immunity  in  this  setting  is  maintained  over  time,  protective  mucosal 
responses  wane  (Figure  7,  9-month  challenge;  Karst  laboratory,  unpublished  data),  indicating  that 
memory immune responses at mucosal sites are not efficiently maintained. There is also evidence from 
the murine model of norovirus infection that repeated norovirus exposure boosts the long-term immune 
response  –  repeated  exposure  to  high-dose  MNV-1  elicits  long-lasting  protective  immunity  [99], 
whereas  single  high-dose  infection  does  not  [88].  The  immunity  elicited  by  repeated  exposure  to 
MNV-1 does appear to be lasting [99]. Interestingly, studies of murine norovirus infection also signify 
that lower doses of virus elicit stronger memory immune responses than high doses [88]. It has yet to 
be determined whether virus dose similarly displays an inverse correlation to protection upon human 
norovirus infection.  
In apparent contradiction to the results of early human volunteer studies, some investigators have 
recently suggested that noroviruses can elicit herd immunity [62,123,129,193]. This supposition is 
based on the epochal pattern of GII.4 pandemics, with emergence of a dominant virus strain for a  
1–2  year  period  followed  by  a  period  of  relative  GII.4  quiescence  prior  to  emergence  of  a  new 
dominant strain (Figure 8) [62]. The emergence of new pandemic GII.4 strains is postulated to result 
from (i) antigenic drift-mediated altered carbohydrate usage and (ii) altered antigenicity facilitating 
virus escape of herd immunity [128,195]. Consistent with this, only a minimal number of amino acid 
changes in the capsid P domain are required to alter HBGA usage, enabling norovirus strains great Viruses 2010, 2                         
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flexibility in evolving to infect new populations [195]. It has also been reported in a recent human 
norovirus challenge study that a subset of secretor-positive volunteers were resistant to Norwalk virus 
infection, and these individuals displayed a modest increase in norovirus-specific salivary IgA early 
after  infection  [123].  While  interesting,  interpretation  of  these  studies  is  complicated  by  several 
factors:  the  previous  exposure  histories  of  the  subjects  are  unknown,  and  it  is  not  possible  to 
distinguish  between  short-  and  long-term  immunity.  Moreover,  these  studies  do  not  offer  an 
explanation  for  the  observation  that  some  individuals  are  susceptible  to  repeated  infections  with 
homologous virus [5,6].  
Figure  7.  Mucosal  norovirus  immunity  wanes  over  time.  Groups  of  129SvEv  mice  
(5–14 mice per group) were mock-infected (1°) or inoculated perorally with 10
4 pfu MNV-
1.CW3 (2°). Six weeks or nine months later, all mice were infected with 10
7 pfu MNV-
1.CW3. One day after secondary challenge, animals were perfused, organs were harvested, 
and viral burden was determined by plaque assay. The data for all mice in each group are 
averaged. Limits of detection are indicated by dashed lines. Fold-reductions for titers in 
mice receiving secondary challenge compared to those in mice receiving primary challenge 
are listed above the black bars. 
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Figure  8.  Epochal  evolution  of  the  GII.4  noroviruses.  Early  GII.4  norovirus  strains 
(Camberwell and Grimsby) persisted for long periods and were followed by shorter periods 
of stasis before being replaced by a new dominant strain. The evolution of GII.4 viruses 
appears to have become much more rapid in recent years, with pandemic strains being 
replaced by a new dominant strain in 1–2 years. FH, Farmington Hills; M, Minerva.  
 
One explanation that would be inclusive of all norovirus immunity observations to date is that short-
term herd immunity drives the evolution of emerging norovirus strains, but this immunity wanes over 
time such that genetically susceptible individuals can be repeatedly infected with homologous virus Viruses 2010, 2                         
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over the long-term. Studies of GII.4 carbohydrate usage may support this idea – while 2002–2005 
strains display distinct binding profiles compared to earlier 1974–1997 strains, the binding profile of 
the more recent 2006 GII.4 strain is similar to those of 1974–1997 strains [63,195].  
6.2. Candidate Norovirus Vaccination Strategies  
Current efforts to design human norovirus vaccines focus on expression of the norovirus capsid 
protein in various vectors, resulting in self-assembly of the capsid protein into immunogenic VLPs [4]. 
Such vaccine candidates elicit both serum IgG and mucosal IgA responses, but the duration of these 
responses and their protective potential have not been determined. A Phase I safety trial has been 
completed for a dry powder norovirus VLP vaccine delivered intranasally in conjunction with a TLR4 
agonist adjuvant; the vaccine was determined to be immunogenic and was not associated with adverse 
side  effects  (http://www.ligocyte.com/downloads/Noro.pdf).  Live  virus  challenge  studies  are  now 
underway.  While  challenge  studies  following  exposure  to  human  norovirus  VLPs  have  not  been 
reported, results from animal models are encouraging: (i) intranasal inoculation of calves with bovine 
norovirus VLPs + adjuvant induces both mucosal and systemic humoral immunity, although protection 
from  subsequent  challenge  is  only  partial  and  viral  shedding  is  not  prevented  [196];  (ii)  repeated 
mucosal exposure to HS66 VLPs + adjuvant elicits immune responses and protection from live HS66 
in  a  majority  of  vaccinated  gnotobiotic  pigs  [197];  (iii)  footpad  inoculation  of  mice  with  murine 
norovirus VLPs + adjuvant induces humoral immune responses and reduced virus loads, although 
protection from disease was not assessed in this study [198]. Additional work with murine norovirus 
suggests that a broad adaptive immune response including B cells, CD4 T cells, and CD8 T cells, is 
critical for full protection [99].  
While  available  information  on  norovirus  VLP-based  vaccines  is  promising,  several  potential 
obstacles require serious consideration. Feline calicivirus vaccines, either modified live vaccines or 
inactivated vaccines given with adjuvants, have been used for many years [95]. These vaccines induce 
protective  immunity  in  cats  in  terms  of  clinical  disease  prevention;  however,  they  do  not  prevent 
infection or persistence. In such a scenario, the presence of non-neutralizing immunity could actually 
induce the emergence of virulent strains [199]. To this end, multiple virulent feline calicivirus isolates 
have recently emerged that cause systemic disease associated with high mortality; vaccinated cats have 
been prominently affected in these outbreaks [200,201]. These data highlight the potential necessity of 
designing norovirus vaccination strategies that target both clinical disease and prolonged infection. 
Other major obstacles in designing norovirus vaccines  are the  genetic  variability within this virus 
family and the replacement of pandemic strains in short time intervals (see Figure 8). These factors 
may  require  a  continually  evolving  vaccine  preparation  similar  to  the  one  currently  in  place  for 
influenza viruses. Moreover, multiple norovirus strains may need to be included in this preparation to 
elicit  effective  immunity  to  each  genogroup.  A  final  possible  hindrance  to  a  successful  norovirus 
vaccine is the inability of natural infection to elicit lasting protection in all individuals. It will be 
critical to delineate the basis for this lack of immunity and to determine whether a similar phenomenon 
occurs upon exposure to candidate norovirus vaccines.  Viruses 2010, 2                         
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7. Conclusions 
Recent advances in the norovirus field have greatly facilitated progress in our understanding of how 
this emerging RNA virus family causes disease and persists worldwide. These advances include the 
identification  and  structural  characterization  of  HBGAs  as  receptors,  the  development  of  animal 
models and a murine norovirus cell culture system, and the design of norovirus infectious clones and 
replicons. While much progress has been made in the human norovirus field, it is still limited by the 
lack of an efficient cell culture model. Designing efficacious norovirus vaccines and therapies with 
broad spectrum activity across the family also remains a major challenge due to several factors: (1) the 
extreme genetic variability within the norovirus family and within genogroups; (2) the rapid evolution 
of antigenically dissimilar pandemic GII.4 norovirus strains; and (3) the lack of lasting immunity upon 
natural  exposure  to  noroviruses  in  at  least  a  proportion  of  the  population.  Studies  in  the  murine 
norovirus model suggest that immunity to natural infection does indeed wane over time but can be 
enhanced by repeat exposure. Moreover, the finding that the HBGA binding interface is conserved 
within a norovirus genogroup may facilitate the development of novel therapeutic strategies that target 
all  members  of  a  specific  genogroup.  As  we  continue  to  expand  our  understanding  of  norovirus 
replication  strategies  using  newly  developed  in  vitro  models,  additional  novel  targets  for  antiviral 
therapies will undoubtedly be revealed. 
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